[HTML][HTML] Artemisinin-resistant malaria: research challenges, opportunities, and public health implications
RM Fairhurst, GML Nayyar, JG Breman… - The American journal …, 2012 - ncbi.nlm.nih.gov
Artemisinin-based combination therapies are the most effective drugs to treat Plasmodium
falciparum malaria. Reduced sensitivity to artemisinin monotherapy, coupled with the …
falciparum malaria. Reduced sensitivity to artemisinin monotherapy, coupled with the …
Glutathione and infection
BACKGROUND: The tripeptide γ-glutamylcysteinylglycine or glutathione (GSH) has
demonstrated protective abilities against the detrimental effects of oxidative stress within the …
demonstrated protective abilities against the detrimental effects of oxidative stress within the …
Artemisinin activity against Plasmodium falciparum requires hemoglobin uptake and digestion
N Klonis, MP Crespo-Ortiz, I Bottova… - Proceedings of the …, 2011 - National Acad Sciences
Combination regimens that include artemisinin derivatives are recommended as first line
antimalarials in most countries where malaria is endemic. However, the mechanism of …
antimalarials in most countries where malaria is endemic. However, the mechanism of …
Artemisinin activity-based probes identify multiple molecular targets within the asexual stage of the malaria parasites Plasmodium falciparum 3D7
The artemisinin (ART)-based antimalarials have contributed significantly to reducing global
malaria deaths over the past decade, but we still do not know how they kill parasites. To gain …
malaria deaths over the past decade, but we still do not know how they kill parasites. To gain …
Is simpler better? Synthetic nicotinamide cofactor analogues for redox chemistry
The topic of synthetic nicotinamide cofactor analogues is resurfacing as new approaches
are being explored, especially in the areas of organic chemistry and biocatalysis. By …
are being explored, especially in the areas of organic chemistry and biocatalysis. By …
A click chemistry‐based proteomic approach reveals that 1, 2, 4‐trioxolane and artemisinin antimalarials share a common protein alkylation profile
In spite of the recent increase in endoperoxide antimalarials under development, it remains
unclear if all these chemotypes share a common mechanism of action. This is important …
unclear if all these chemotypes share a common mechanism of action. This is important …
Synthetic Peroxides Promote Apoptosis of Cancer Cells by Inhibiting P‐Glycoprotein ABCB5
This article discloses a new horizon for the application of peroxides in medical chemistry.
Stable cyclic peroxides are demonstrated to have cytotoxic activity against cancer cells; in …
Stable cyclic peroxides are demonstrated to have cytotoxic activity against cancer cells; in …
Novel peroxides as promising anticancer agents with unexpected depressed antimalarial activity
Twenty six peroxides belonging to bridged 1, 2, 4, 5‐tetraoxanes, bridged 1, 2, 4‐trioxolanes
(ozonides), and tricyclic monoperoxides were evaluated for their in vitro antimalarial activity …
(ozonides), and tricyclic monoperoxides were evaluated for their in vitro antimalarial activity …
Considerations on the mechanism of action of artemisinin antimalarials: Part 1-The'carbon radical'and'heme'hypotheses
R K. Haynes, KW Cheu, D N'Da… - Infectious Disorders …, 2013 - benthamdirect.com
The isolation of artemisinin from the traditional medicinal herb qīng hāo (Artemisia annua),
its characterization as a peroxide and preparation of the derivatives dihydroartemisinin …
its characterization as a peroxide and preparation of the derivatives dihydroartemisinin …
[HTML][HTML] Methylene blue for treatment of hospitalized COVID-19 patients: a randomized, controlled, open-label clinical trial, phase 2
D Hamidi-Alamdari, S Hafizi-Lotfabadi… - Revista de …, 2021 - scielo.org.mx
HAMIDI-ALAMDARI, Daryoush et al. Methylene Blue for Treatment of Hospitalized COVID-
19 Patients: A Randomized, Controlled, Open-Label Clinical Trial, Phase 2. Rev. invest …
19 Patients: A Randomized, Controlled, Open-Label Clinical Trial, Phase 2. Rev. invest …